Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Pulmonology

   News

   Conferences

   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to Chest Diseases

Alpha 1-antitrypsin deficiency

Alpha 1-antitrypsin deficiency (A1AD) is a genetic disorder caused by reduced levels of alpha 1-antitrypsin in blood. It leads to pulmonary (lung) emphysema and, in severe cases, to liver disease.

Epidemiology

Northwest Europeans are at the highest risk for A1AD, with 4% carrying the PiZ allele and - therefore - a risk of homozygosity in about 1:625 to 1:2000.

Associated diseases

α1-antitrypsin deficiency has been associated with a number of diseases:

  • Asthma
  • Wegener's granulomatosis
  • Pancreatitis
  • Gallstones
  • Bronchiectasia (possibly)
  • Prolapse
  • Cancer
    • Hepatocellular carcinoma (liver)
    • Bladder carcinoma
    • Gallbladder carcinoma
    • Lymphoma
    • Lung cancer

Signs and symptoms

These are generally undistinguishable from the "normal" emphysema and cirrhosis.

Pathophysiology

Please refer to the alpha 1-antitrypsin for the various protease inhibitor (Pi) genotypes and phenotypes.

Normally, alpha 1-antitrypsin is produced in the liver and exists in levels of 1.5-3.5 gram/litre. When the levels are reduced (40-60%, in the PiSS, PiMZ and PiSZ phenotypes), most people will only suffer symptoms if they smoke, as the levels are still sufficient to counteract "normal" elastase activity in inflammation. Only in the PiZZ phenotype, when the levels are less than 15%, emphysema develops at a young age, and 50% will develop liver cirrhosis due to the accumulated protein, which is not secreted properly. On liver biopsy, they show as PAS-positive, diastase-negative granules.

Apart from increasing the inflammatory reaction in the airways, cigarette smoke also directly inactivates alpha 1-antitrypsin by oxidizing essential methionine residues to sulfoxide forms, decreasing the enzyme activity by a rate of 2000.

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


Treatment

There is no specific treatment for A1AD; present management is identical for the "normal" treatment of emphysema and cirrhosis.

As α1-antitrypsin is an acute phase reactant, its transcription is markedly increased during inflammation elsewhere in response to increased interleukin-1 and 6 and TNFα production. Any treatment that blunts this response, specifically paracetamol, can delay the accumulation of A1AD polymers in the liver and (hence) cirrhosis. A1AT patients are therefore encouraged to use paracetamol when slightly to moderately ill, even if they would otherwise not have used antipyretics.

Experimental therapies are aimed at the prevention of polymer formation in the liver.

previous.gif (72x17 -- 347 bytes) next.gif (72x17 -- 277 bytes)
 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.